"Drs. Brett Miles and Marshall Posner - FDA Awards Grant for Phase 2 Study of Immunotherapy Drug used in HPV-Associated Head and Neck Cancer"
The US Food and Drug Administration Office of Orphan Products Development (OOPD) awarded a grant totaling $1.1 million over three years in support of an ongoing phase 2 trial of a new immunotherapy in HPV-associated oropharynx cancer, a type of head and neck cancer. Brett Miles, MD, and Marshall Posner, MD, at the Icahn School of Medicine at Mount Sinai will serve as key investigators. Learn more